BRPI0609595A8 - composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares - Google Patents

composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares Download PDF

Info

Publication number
BRPI0609595A8
BRPI0609595A8 BRPI0609595A BRPI0609595A BRPI0609595A8 BR PI0609595 A8 BRPI0609595 A8 BR PI0609595A8 BR PI0609595 A BRPI0609595 A BR PI0609595A BR PI0609595 A BRPI0609595 A BR PI0609595A BR PI0609595 A8 BRPI0609595 A8 BR PI0609595A8
Authority
BR
Brazil
Prior art keywords
methods
compositions
obesity
prevention
treatment
Prior art date
Application number
BRPI0609595A
Other languages
English (en)
Inventor
Weyer Christian
M Mack Christine
G Parkes David
D Laugero Kevin
Original Assignee
Amylin Pharmaceuticals Inc
Amylin Pharmaceuticals Llc
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc, Amylin Pharmaceuticals Llc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Inc
Publication of BRPI0609595A2 publication Critical patent/BRPI0609595A2/pt
Publication of BRPI0609595A8 publication Critical patent/BRPI0609595A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

uso de amilina ou agonista de amilina e composição farmacêutica compreendendo os mesmos. a presente invenção refere-se a composições e métodos para prevenir, tratar ou controlar condições ou distúrbios associados com obesidade, dieta, e nutrição. os métodos fornecidos envolvem geralmente a administração de amilina ou um agonista de amilina a um indivíduo a fim de prevenir, tratar ou controlar condições e distúrbios associados com obesidade, dieta e nutrição.
BRPI0609595A 2005-03-31 2006-03-31 composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares BRPI0609595A8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US66668105P 2005-03-31 2005-03-31
US66733505P 2005-03-31 2005-03-31
US60/666,681 2005-03-31
US60/667,335 2005-03-31
US67544105P 2005-04-28 2005-04-28
US60/675,441 2005-04-28
US76058306P 2006-01-20 2006-01-20
US60/760,583 2006-01-20
PCT/US2006/011768 WO2006105345A2 (en) 2005-03-31 2006-03-31 Compositions and methods for the control, prevention, and treatment of obesity and eating disorders

Publications (2)

Publication Number Publication Date
BRPI0609595A2 BRPI0609595A2 (pt) 2010-04-20
BRPI0609595A8 true BRPI0609595A8 (pt) 2018-05-15

Family

ID=37054153

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0609595A BRPI0609595A8 (pt) 2005-03-31 2006-03-31 composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares
BRPI0606466-3A BRPI0606466A2 (pt) 2005-03-31 2006-03-31 amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0606466-3A BRPI0606466A2 (pt) 2005-03-31 2006-03-31 amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos

Country Status (17)

Country Link
US (7) US7671023B2 (pt)
EP (5) EP2248527A3 (pt)
JP (2) JP5114381B2 (pt)
KR (3) KR101383493B1 (pt)
CN (3) CN101189021B (pt)
AT (2) ATE439140T1 (pt)
AU (2) AU2006230602B2 (pt)
BR (2) BRPI0609595A8 (pt)
CA (2) CA2602261A1 (pt)
DE (2) DE602006008456D1 (pt)
DK (1) DK1888094T3 (pt)
EA (1) EA013121B1 (pt)
ES (1) ES2330671T3 (pt)
IL (1) IL186200A (pt)
MX (2) MX2007012236A (pt)
NZ (3) NZ561936A (pt)
WO (2) WO2006105527A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602005021858D1 (de) * 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7671023B2 (en) 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
KR20080106950A (ko) * 2006-03-31 2008-12-09 아밀린 파마슈티칼스, 인크. 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN102076353A (zh) * 2008-06-25 2011-05-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
WO2010046357A1 (en) * 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
JP2012523434A (ja) * 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CA2758976C (en) 2009-04-20 2015-02-03 Alain Baron Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
US20110317346A1 (en) 2010-06-28 2011-12-29 Zte Corporation Totally-enclosed integrative access system and power consumption reduction method thereof
EP2630491A4 (en) 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2721062T3 (pl) * 2011-06-17 2019-05-31 Hanmi Science Co Ltd Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
EP2807187B1 (en) * 2012-01-26 2017-07-26 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
EP3027644B1 (en) * 2013-07-30 2019-08-21 Christopher J. Soares Cgrp agonist peptides
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3506925B1 (en) 2016-09-02 2023-09-06 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
EP3628233B1 (en) * 2018-09-28 2021-06-02 Siemens Healthcare GmbH Method and system for providing a dose reference value for a patient
US11443843B2 (en) 2019-01-04 2022-09-13 International Business Machines Corporation Personal customized guidance for treating patients
EP3923919A4 (en) 2019-02-17 2022-12-07 Neurawell Therapeutics COMPOSITIONS AND METHODS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES
CN111700904A (zh) * 2020-07-31 2020-09-25 江南大学 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法
JP2024527578A (ja) * 2021-07-08 2024-07-25 ギラ セラピューティクス インコーポレイテッド 神経受容体を活性化するための組成物及び方法
TW202528338A (zh) * 2023-12-04 2025-07-16 丹麥商西蘭製藥公司 方法
WO2025120001A1 (en) * 2023-12-04 2025-06-12 Zealand Pharma A/S Amylin analogues for reducing consumption of high-fat food

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024807B1 (en) 1979-07-28 1983-11-02 Beecham Group Plc Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
US4397780A (en) 1982-02-12 1983-08-09 Armour Pharmaceutical Company Leucine22 -calcitonin
US4401593A (en) 1982-02-12 1983-08-30 Armour Pharmaceutical Company Glycine - 8 calcitonin
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4497731A (en) 1983-04-04 1985-02-05 Armour Pharmaceutical Company Glycine 8-des-tyrosine 22 calcitonin
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
US4597900A (en) 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
US4537716A (en) 1983-12-05 1985-08-27 Armour Pharmaceutical Co. Des-serine2 or des-glycine2 -leucine22 calcitonin
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4604238A (en) 1984-12-10 1986-08-05 Armour Pharmaceutical Company Analogs of calcitonin
US4606856A (en) 1985-03-18 1986-08-19 Seyler Jay K [Des-1-amino, 8-glycine]calcitonin
US4652627A (en) 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en) 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en) 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5405831A (en) 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
MD960317A (ro) * 1991-11-19 1998-05-31 Anylin Pharmaceuticals, Inc. Noile peptide-agoniste ale amilinei şi utilizarea lor
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US5589356A (en) 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
BR9407424A (pt) 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US6307018B1 (en) 1996-12-24 2001-10-23 The Scripps Research Institute General chemical ligation
PT1629849E (pt) * 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US20040022807A1 (en) 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
EP1001968B1 (en) 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
EP1091440B1 (en) 1998-05-29 2010-06-02 JGC Catalysts and Chemicals Ltd. Method of manufacturing photoelectric cell
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
KR20010085743A (ko) 1998-08-31 2001-09-07 추후제출 지질 매트릭스 보조 화학결합 및 막 폴리펩티드의 합성
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
ATE500838T1 (de) 2000-09-08 2011-03-15 Amylin Pharmaceuticals Inc ßPSEUDOß-NATIVE CHEMISCHE LIGATION
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
WO2003042235A2 (en) 2001-11-14 2003-05-22 Geneprot, Inc. Extended native chemical ligation of three or more peptide fragments
DE60324387D1 (de) 2002-01-08 2008-12-11 Amylin Pharmaceuticals Inc Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
MY133587A (en) * 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
US7566697B2 (en) 2002-06-10 2009-07-28 Amylin Pharmaceuticals, Inc. Carboxy protection strategies for acidic C-terminal amino acids in chemical ligation of oligopeptides
WO2004048547A2 (en) 2002-11-26 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
WO2004060925A2 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Multiplex polymer ligation
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
WO2004105685A2 (en) 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2005295043A1 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
US7671023B2 (en) 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia

Also Published As

Publication number Publication date
EA013121B1 (ru) 2010-02-26
US8389477B2 (en) 2013-03-05
EP2248527A2 (en) 2010-11-10
CN101189021A (zh) 2008-05-28
AU2006230602B2 (en) 2010-07-15
EP2258382A3 (en) 2014-05-14
JP2008534627A (ja) 2008-08-28
DE602006016760D1 (de) 2010-10-21
BRPI0609595A2 (pt) 2010-04-20
WO2006105345A9 (en) 2007-03-22
KR20130122983A (ko) 2013-11-11
EP1888094A2 (en) 2008-02-20
JP5415067B2 (ja) 2014-02-12
MX2007012236A (es) 2007-12-06
CA2602584A1 (en) 2006-10-05
US20130225485A1 (en) 2013-08-29
CN102343084A (zh) 2012-02-08
US7671023B2 (en) 2010-03-02
NZ578299A (en) 2010-03-26
ATE480255T1 (de) 2010-09-15
KR101383493B1 (ko) 2014-04-11
EP2248527A3 (en) 2013-04-03
DK1888094T3 (da) 2009-11-09
US7879794B2 (en) 2011-02-01
IL186200A0 (en) 2008-01-20
JP5114381B2 (ja) 2013-01-09
AU2006230420B2 (en) 2011-11-24
AU2006230420A1 (en) 2006-10-05
CN101415435A (zh) 2009-04-22
NZ578298A (en) 2010-07-30
WO2006105345A2 (en) 2006-10-05
IL186200A (en) 2013-09-30
CN101189021B (zh) 2011-12-14
EP2135617A3 (en) 2013-09-18
EP1871403A2 (en) 2008-01-02
US20100125054A1 (en) 2010-05-20
WO2006105527A3 (en) 2007-01-11
EA200702126A1 (ru) 2008-04-28
ATE439140T1 (de) 2009-08-15
MX2007012237A (es) 2007-12-07
NZ561936A (en) 2009-07-31
EP1871403B1 (en) 2010-09-08
EP2135617A2 (en) 2009-12-23
BRPI0606466A2 (pt) 2009-06-30
EP2258382A2 (en) 2010-12-08
US20130184213A1 (en) 2013-07-18
US20090062193A1 (en) 2009-03-05
US8278267B2 (en) 2012-10-02
DE602006008456D1 (de) 2009-09-24
EP1888094B1 (en) 2009-08-12
KR20070119718A (ko) 2007-12-20
WO2006105345A3 (en) 2007-02-01
CA2602261A1 (en) 2006-10-05
US20110263491A1 (en) 2011-10-27
KR20080003849A (ko) 2008-01-08
ES2330671T3 (es) 2009-12-14
JP2008534606A (ja) 2008-08-28
US20110288028A1 (en) 2011-11-24
WO2006105527A2 (en) 2006-10-05
AU2006230602A1 (en) 2006-10-05
US20080287355A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0606466A2 (pt) amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos
MX387010B (es) Inhibidor de sglt-2 para el tratamiento de diabetes mellitus tipo 1, diabetes mellitus tipo 2, tolerancia deteriorada a la glucosa o hiperglucemia.
MX279139B (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
IL191865A0 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL191864A0 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
JO2872B1 (en) New vehicles
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
WO2008048991A3 (en) Organic compounds
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
MA30392B1 (fr) Composes organiques et leurs utilisations
WO2008029169A3 (en) Method of treating respiratory disorders
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
DK2332408T3 (da) Behandling af neurologiske sygdomme
PT2236608T (pt) Péptidos novos para tratar e prevenir distúrbios relacionados com a imunidade, incluindo tratar e prevenir infecção por modulação da imunidade inata
WO2008033477A3 (en) Antimicrobial activity in variants of lacritin
BRPI0720158A2 (pt) Agentes para terapia e/ou melhora de coagulação intravascular disseminada, para reduzir a probabilidade de morte em pacientes sofrendo da mesma, métodos para selecionar pacientes, e, para tratar e/ou melhorar coagulação intravascular disseminada
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2008031034A3 (en) Therapeutic compounds for diseases and disorders
WO2005107767A3 (en) Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
WO2006107902A8 (en) Use of spirostenols to treat mitochondrial disorders
WO2006116660A3 (en) Methods of inhibiting a gpr23

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AMYLIN PHARMACEUTICALS, LLC (US)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA PHARMACEUTICALS LP (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.